Abstract
Noncommunicable diseases such as cardiovascular diseases and cancers are key threats to maintaining health and well-being in the twenty-first century. In 2008, 30 % of global deaths were due to cardiovascular disease, a mortality burden felt by countries across the income/development spectrum. The middle of the twentieth century saw the advent of epidemiological studies which have made significant advances in understanding the factors driving cardiovascular disease risk. Studies such as the Seven Countries Study gathered data from across the globe on clinical and lifestyle factors and their relationship to rates of cardiovascular disease. Other landmark studies such as the Framingham Study set the scene for a detailed understanding of the magnitude of risk conferred by clinical factors.
An increasingly sedentary lifestyle and energy-dense diet facilitated by urbanization have contributed to epidemics of obesity, hypertension, and diabetes, which are all major cardiovascular risk factors. These risks, coupled with aging populations (age being another key risk factor), drive the need to develop and implement prevention strategies that will be effective and accessible for high- and lower-income countries. The worldwide framework for tobacco control and working with the food industry to develop healthier accessible foods are key examples of lifestyle-related strategies for prevention. Low-cost preventive medications such as the multicomponent “polypill” also hold promise as cost-effective strategies to reduce the burden of cardiovascular disease; however further evidence of the efficacy across different population and age groups is required.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Allhat Officers and Coordinators for the Allhat Collaborative Research Group. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, 2981–2997.
Antiplatelet Triallists Collaboration. (1994). Collaborative overview of randomised trials of antiplatelet treatment. British Medical Journal, 308, 235–246.
Aspree Study Group. (2013). Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial. Contemporary Clinical Trials, 36, 555–564.
Bishopric, N. H. (2013). Toward a genomic definition of aspirin resistance∗. Journal of the American College of Cardiology, 62, 1277–1279.
Brand, R. J., Paffenbarger, R. S., Jr., Sholtz, R. I., & Kampert, J. B. (1979). Work activity and fatal heart attack studied by multiple logistic risk analysis. American Journal of Epidemiology, 110, 52–62.
Bulpitt, C. J., Beckett, N. S., Peters, R., Leonetti, G., Gergova, V., Fagard, R., Burch, L. A., Banya, W., & Fletcher, A. E. (2012). Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension, 26, 157–163.
Bunker, S., Colquhoun, D. J., Esler, M., Hickie, I., Hunt, D., Jelinek, M., Oldenburg, B., Peach, H., Ruth, D., Tennant, C., & Tonkin, A. (2003). “Stress” and coronary heart disease: Psychosocial risk factors. Medical Journal of Australia, 178, 272–276.
Chomistek, A. K., Manson, J. E., Stefanick, M. L., Lu, B., Sands-Lincoln, M., Going, S. B., Garcia, L., Allison, M. A., Sims, S. T., Lamonte, M. J., Johnson, K. C., & Eaton, C. B. (2013). Relationship of sedentary behavior and physical activity to incident cardiovascular disease: Results from the Women’s Health Initiative. Journal of the American College of Cardiology, 61, 2346–2354.
Colquhoun, D., Bunker, S., Clarke, D., Glozier, N., Hare, D. L., Hickie, I. B., Tatoulis, J., Thompson, D. R., Tofler, G. H., Wilson, A., & Branagan, M. G. (2013a). Screening, referral and treatment for depression in patients with coronary heart disease. Medical Journal of Australia, 198, 483–484.
Colquhoun, D. M., Bunker, S. J., Clarke, D. M., Hare, D. L., Hickie, I. B., Tatoulis, J., Thompson, D. R., Wilson, A., & Branagan, M. G. (2013b). Psychosocial risk factors for coronary heart disease. The Medical Journal of Australia, 199, 1–6.
Cook, D. G., Shaper, A. G., Pocock, S. J., & Kussick, S. J. (1986). Giving up smoking and the risk of heart attacks. Lancet, ii, 1376–1380.
D’Agostino, R. B., Sr., Pencina, M. J., Massaro, J. M., & Coady, S. (2013). Cardiovascular disease risk assessment: Insights from Framingham. Global Heart, 8, 11–23.
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., Mcinnes, G. T., Mehlsen, J., Nieminen, M., O’Brien, E., & Östergren, J. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. The Lancet, 366, 895–906.
Dawber, T. R. (1980). The Framingham study. Cambridge, MA: Harvard University Press.
Dietrich, T., Sharma, P., Walter, C., Weston, P., & Beck, J. (2013). The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. Journal of Periodontology, 84, S70–S84.
Doll, R., & Peto, R. (1976). Mortality in relation to smoking: 20 years’ observations on male British doctors. British Medical Journal, 2, 1525–1536.
Dyer, A. R., Stamler, J., Paul, O., Berkson, D. M., Shekelle, R. B., Lepper, M. H., Mckean, H., Lindberg, H. A., Garside, D., & Tokich, T. (1981). Alcohol, cardiovascular risk factors and mortality: The Chicago experience. Circulation, 64, III 20–III 27.
Everett, B. M., Glynn, R. J., Macfadyen, J. G., & Ridker, P. M. (2010). Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER). Circulation, 121, 143–150.
Fetcher, E. S., Foster, N., Anderson, J. T., Grande, F., & Keys, A. (1967). Quantitative estimation of diets to control serum cholesterol. American Journal of Clinical Nutrition, 20, 475–492.
Fox, C. S., Coady, S., Sorlie, P. D., D’Agostino, R. B., Sr., Pencina, M. J., Vasan, R. S., Meigs, J. B., Levy, D., & Savage, P. J. (2007). Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation, 115, 1544–1550.
Friedman, G. D., Klatsky, A. L., & Siegelaub, A. B. (1974). The leukocyte count as a predictor of myocardial infarction. New England Journal of Medicine, 290, 1275–1278.
Friedman, L., Wenger, N. K., & Knatterud, G. L. (1983). Impact of the coronary drug project findings on clinical practice. Controlled Clinical Trials, 4, 513–522.
Gersh, B. J., Sliwa, K., Mayosi, M. B., Yusuf, S. (2010). Novel therapeutic concepts. The epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J, 31(6), 642–648.
Gordon, T., Kannel, W. B., Mcgee, D., & Dawber, T. (1974). Death and coronary attacks in men after giving up cigarette smoking. Lancet, ii, 1345–1348.
He, F. J., & Macgregor, G. A. (2003). How far should salt intake be reduced? Hypertension, 42, 1093–1099.
Held, C., Iqbal, R., Lear, S. A., Rosengren, A., Islam, S., Mathew, J., & Yusuf, S. (2012). Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: Results of the INTERHEART study. European Heart Journal, 33, 452–466.
Hotchkiss, J. W., Davies, C. A., Dundas, R., Hawkins, N., Jhund, P. S., Scholes, S., Bajekal, M., O’Flaherty, M., Critchley, J., Leyland, A. H., & Capewell, S. (2014). Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: Retrospective analysis using routine data. BMJ, 348, g1088.
Hypertension Detection Follow-Up Program Cooperative Group. (1979). Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA, 242, 2562–2571.
Kagan, A., Gordon, T., Rhoads, G. G., & Schiffman, J. C. (1975). Some factors related to coronary heart disease incidence in Honolulu Japanese men: The Honolulu Heart Study. International Journal of Epidemiology, 4, 271–279.
Keys, A. (1970). Coronary heart disease in seven countries. Summary. Circulation, 41, I186–I195.
Keys, A., Menotti, A., Aravanis, C., Blackburn, H., Djordevic, B. S., Buzina, R., Dontas, A. S., Fidanza, F., Karvonen, M. J., Kimura, N., et al. (1984). The seven countries study: 2,289 deaths in 15 years. Preventive Medicine, 13, 141–154.
Krum, H., Schlaich, M. P., Sobotka, P. A., Böhm, M., Mahfoud, F., Rocha-Singh, K., Katholi, R., & Esler, M. D. (2014). Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the symplicity HTN-1 study. The Lancet, 383, 622–629.
Lawes, C. M., Vander Hoorn, S., & Rodgers, A. (2008). Global burden of blood-pressure-related disease, 2001. Lancet, 371, 1513–1518.
Leong, D. P., Smyth, A., Teo, K. K., McKee, M., Rangarajan, S., Pais, P., Liu, L., Anand, S. S., & Yusuf, S. (2014). Patterns of alcohol consumption and myocardial infarction risk: Observations from 52 countries in the INTERHEART Case-Control Study. Circulation, 130(5), 390–398.
Lewington, S., Clarke, R., Qizilbash, N., Peto, R., & Collins, R. (2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903–1913.
Lloyd-Jones, D. M., Nam, B. H., D’Agostino, R. B., Sr., Levy, D., Murabito, J. M., Wang, T. J., Wilson, P. W., & O’Donnell, C. J. (2004). Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: A prospective study of parents and offspring. JAMA, 291, 2204–2211.
Lu, Y., Hajifathalian, K., Ezzati, M., Woodward, M., Rimm, E. B., & Danaei, G. (2014). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: A pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet, 383, 970–983.
Marmot, M. G., Syme, S. L., Kagan, A., Kato, H., Cohen, J. B., & Belsky, J. (1975). Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: Prevalence of coronary and hypertensive heart disease and associated risk factors. American Journal of Epidemiology, 102, 514–525.
Meade, T. (2001). Cardiovascular disease – Linking pathology and epidemiology. International Journal of Epidemiology, 30, 1179–1183.
Members, A. T. F., Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D. E., Jaarsma, T., Kirchhof, P., Kjeldsen, S. E., Laurent, S., Manolis, A. J., Nilsson, P. M., Ruilope, L. M., Schmieder, R. E., Sirnes, P. A., Sleight, P., Viigimaa, M., Waeber, B., Zannad, F., Council, E. S., Burnier, M., Ambrosioni, E., Caufield, M., Coca, A., Olsen, M. H., Tsioufis, C., Van de Borne, P., Guidelines, E. C. F. P., Zamorano, J. L., Achenbach, S., Baumgartner, H., Bax, J. J., Bueno, H., Dean, V., Deaton, C., Erol, C., Ferrari, R., Hasdai, D., Hoes, A. W., Knuuti, J., Kolh, P., Lancellotti, P., Linhart, A., Nihoyannopoulos, P., Piepoli, M. F., Ponikowski, P., Tamargo, J. L., Tendera, M., Torbicki, A., Wijns, W., Windecker, S., Reviewers, D., Clement, D. L., Gillebert, T. C., Rosei, E. A., Anker, S. D., Bauersachs, J., Hitij, J. B., Caulfield, M., De Buyzere, M., De Geest, S., Derumeaux, G. A., Erdine, S., Farsang, C., Funck-Brentano, C., Gerc, V., Germano, G., Gielen, S., Haller, H., Jordan, J., Kahan, T., Komajda, M., Lovic, D., Mahrholdt, H., Ostergren, J., Parati, G., Perk, J., Polonia, J., Popescu, B. A., Reiner, Ž., Rydén, L., Sirenko, Y., Stanton, A., Struijker-Boudier, H., Vlachopoulos, C., Volpe, M., & Wood, D. A. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34, 2159–2219.
Morris, J. N., Heady, J. A., Raffle, P. A., Roberts, C. G., & Parks, J. W. (1953). Coronary heart-disease and physical activity of work. Lancet, 265, 1111–1120. concl.
Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J., & Willett, W. C. (2006). Trans fatty acids and cardiovascular disease. New England Journal of Medicine, 354, 1601–1613.
Neaton, J. D., & Wentworth, D. (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Archives of Internal Medicine, 152, 56–64.
World Health Organisation. (2013). Global Health Observatory (GHO): Obesity 2008. WHO, Geneva, Switzerland. http://www.who.int/gho/ncd/risk_factors/obesity_text/en/.
Mendis, S. P. P., & Norrving, B. (Eds.). (2011). Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization.
Patel, A., Cass, A., Peiris, D., Usherwood, T., Brown, A., Jan, S., Neal, B., Hillis, G.S., Rafter, N., Tonkin, A., Webster, R., Billot, l., Bompoint, S., Burch, C., Burke, H., Hayman, N., Molanus, B., Reid, C.M., Shiel, l., Togni, S., Rodgers, A., Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. (2014). A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology. doi:10.1177/2047487314530382. Paper version Eur J Prev Cardiol 2015, 22(7), 920–930
Psaty, B. M., & Weiss, N. S. (2014). 2013 acc/aha guideline on the treatment of blood cholesterol: A fresh interpretation of old evidence. JAMA, 311, 461–462.
Reid, D. D., Hamilton, P. J., McCartney, P., Rose, G., Jarrett, R. J., & Keen, H. (1976). Smoking and other risk factors for coronary heart-disease in British civil servants. Lancet, 2, 979–984.
Ronksley, P. E., Brien, S. E., Turner, B. J., Mukamal, K. J., & Ghali, W. A. (2011). Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ, 342, d671.
Rose, G. (1985). Sick individuals and sick populations. International Journal of Epidemiology, 14, 32–38.
Rosenthal, S. R. (1934). Studies in atherosclerosis: Chemical, experimental, and morphologic. Archives of Pathology, 18, 473–506.
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Ross, L. A., Macfarlane, P. W., Mckillop, J. H., Packard, C. J., & West of Scotland Coronary Prevention Study Group. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The New England Journal of Medicine, 333, 1301–1307.
Smith, W. C., Shewry, M. C., Tunstall-Pedoe, H., Crombie, I. K., & Tavendale, R. (1990). Cardiovascular disease in Edinburgh and north Glasgow – A tale of two cities. Journal of Clinical Epidemiology, 43, 637–643.
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., & For the Syst-Eur Trial Investigators. (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 350, 757–764.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349–1357.
The Scandinavian Simvastatin Survival Study Group. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 344, 1383–1389.
Tsakos, G., Sabbah, W., Hingorani, A. D., Netuveli, G., Donos, N., Watt, R. G., & D’Aiuto, F. (2010). Is periodontal inflammation associated with raised blood pressure? Evidence from a National US survey. Journal of Hypertension, 28, 2386–2393.
Van der Ploeg, H. P., Chey, T., Korda, R. J., Banks, E., & Bauman, A. (2012). Sitting time and all-cause mortality risk in 222 497 Australian adults. Archives of Internal Medicine, 172, 494–500.
Verma, N., & Figueredo, V. M. (2014). HDL cholesterol: All hope is not lost after the torcetrapib setback – Emerging therapeutic strategies on the horizon. American Journal of Therapeutics, 21, 222–232. doi:10.1097/MJT.0b013e318249a1b5.
Veterans Administration Cooperation Study on Antihypertensive Agents. (1970). Effects of treatment of morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA, 213, 1143.
Wang, Y., Zhang, Y., Zhang, J., Tang, X., Qian, Y., Gao, P., & Zhu, D. (2013). Association of a functional single-nucleotide polymorphism in the ALDH2 gene with essential hypertension depends on drinking behavior in a Chinese Han population. Journal of Human Hypertension, 27, 181–186.
Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G., Flack, J. M., Carter, B. L., Materson, B. J., Ram, C. V. S., Cohen, D. L., Cadet, J.-C., Jean-Charles, R. R., Taler, S., Kountz, D., Townsend, R. R., Chalmers, J., Ramirez, A. J., Bakris, G. L., Wang, J., Schutte, A. E., Bisognano, J. D., Touyz, R. M., Sica, D., & Harrap, S. B. (2014). Clinical practice guidelines for the management of hypertension in the community. The Journal of Clinical Hypertension, 16, 14–26.
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047–1053.
Wing, L., Reid, C., Ryan, P., Beilin, L., Brown, M., Jennings, G., Johnston, C., Mcneil, J., Marley, J., Morgan, T., Shaw, J., Steven, I., & West, M. (2003). A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for the treatment of hypertension in the elderly. New England Journal of Med, 348, 583–592.
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., Mcqueen, M., Budaj, A., Pais, P., Varigos, J., & Lisheng, L. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 364, 937–952.
Zacher, M., Bayly, M., Brennan, E., Dono, J., Miller, C., Durkin, S., Scollo, M., & Wakefield, M. (2014). Personal tobacco pack display before and after the introduction of plain packaging with larger pictorial health warnings in Australia: An observational study of outdoor café strips. Addiction, 109, 653–662.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Singapore
About this entry
Cite this entry
Reid, C., Owen, A. (2016). Epidemiology of Cardiovascular Disease. In: Alvarenga, M., Byrne, D. (eds) Handbook of Psychocardiology. Springer, Singapore. https://doi.org/10.1007/978-981-287-206-7_5
Download citation
DOI: https://doi.org/10.1007/978-981-287-206-7_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-287-205-0
Online ISBN: 978-981-287-206-7
eBook Packages: Behavioral Science and PsychologyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences